Development of novel high-affinity nanobodies against EGFR for cancer therapy
Mauro Heitrich, Marisa Mariel Fernández, Diana C. Aguilar-Cortes, Santiago Werbajh, Gabriela Canziani, Vanesa Zylberman, Luisina Belén Ripari, Guillermo A. Videla-Richardson, Emilio Luis Malchiodi, Osvaldo Luis Podhajcer, Sabrina E. Vinzón
This paper isolates and characterizes two high-affinity nanobodies against EGFR, showing their potent anti-tumor activity in vitro.
bioRxiv · Mar 16, 2025 · PreprintMolecular Biology